Symmetry Partners’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $3.84M | Sell |
3,315
-10
| -0.3% | -$11.8K | 0.2% | 50 |
|
|
2026
Q2 | $3.99M | Buy |
3,325
+1,031
| +45% | +$1.05M | 0.2% | 48 |
|
|
2026
Q1 | $2.11M | Sell |
2,294
-14
| -0.6% | -$14.2K | 0.12% | 60 |
|
|
2025
Q4 | $2.48M | Sell |
2,308
-11
| -0.5% | -$10.5K | 0.15% | 56 |
|
|
2025
Q3 | $1.77M | Buy |
2,319
+380
| +20% | +$283K | 0.19% | 55 |
|
|
2025
Q2 | $1.51M | Sell |
1,939
-20
| -1% | -$15.5K | 0.19% | 54 |
|
|
2025
Q1 | $1.62M | Sell |
1,959
-57
| -3% | -$47.4K | 0.23% | 50 |
|
|
2024
Q4 | $1.56M | Buy |
2,016
+1,561
| +343% | +$1.29M | 0.22% | 51 |
|
|
2024
Q3 | $403K | Sell |
455
-10,817
| -96% | -$9.7M | 0.1% | 64 |
|
|
2024
Q2 | $10.2M | Sell |
11,272
-3,922
| -26% | -$3.14M | 0.53% | 45 |
|
|
2024
Q1 | $11.8M | Hold |
15,194
| – | – | 0.93% | 32 |
|
|
2023
Q4 | $8.82M | Sell |
15,194
-939
| -6% | -$548K | 0.48% | 48 |
|
|
2023
Q3 | $8.67M | Sell |
16,133
-434
| -3% | -$224K | 0.47% | 48 |
|
|
2023
Q2 | $7.77M | Hold |
16,567
| – | – | 0.41% | 51 |
|
|
2023
Q1 | $5.69M | Buy |
16,567
+379
| +2% | +$128K | 0.31% | 50 |
|
|
2022
Q4 | $5.92M | Hold |
16,188
| – | – | 0.35% | 47 |
|
|
2022
Q3 | $5.23M | Sell |
16,188
-155
| -0.9% | -$49.1K | 0.35% | 48 |
|
|
2022
Q2 | $5.3M | Buy |
16,343
+4,128
| +34% | +$1.24M | 0.36% | 44 |
|
|
2022
Q1 | $3.5M | Buy |
12,215
+1,286
| +12% | +$331K | 0.22% | 55 |
|
|
2021
Q4 | $3.02M | Buy |
10,929
+3,998
| +58% | +$1.01M | 0.19% | 67 |
|
|
2021
Q3 | $1.6M | Sell |
6,931
-268
| -4% | -$66.1K | 0.11% | 124 |
|
|
2021
Q2 | $1.65M | Hold |
7,199
| – | – | 0.11% | 127 |
|
|
2021
Q1 | $1.34M | Sell |
7,199
-1,097
| -13% | -$215K | 0.1% | 145 |
|
|
2020
Q4 | $1.4M | Sell |
8,296
-3,146
| -27% | -$470K | 0.11% | 129 |
|
|
2020
Q3 | $1.69M | Buy |
11,442
+4,418
| +63% | +$684K | 0.14% | 92 |
|
|
2020
Q2 | $1.15M | Buy |
+7,024
| New | +$1.08M | 0.14% | 71 |
|
|
2019
Q4 | – | Sell |
-7,866
| Closed | -$880K | – | 354 |
|
|
2019
Q3 | $880K | Sell |
7,866
-6,776
| -46% | -$754K | 0.18% | 70 |
|
|
2019
Q2 | $1.62M | Sell |
14,642
-2,117
| -13% | -$249K | 0.33% | 48 |
|
|
2019
Q1 | $2.18M | Buy |
16,759
+8,121
| +94% | +$988K | 0.37% | 39 |
|
|
2018
Q4 | $1M | Buy |
+8,638
| New | +$965K | 0.25% | 57 |
|
Other funds holding LLY
Symmetry Partners's LLY Position: Q3 2026 in Review
Symmetry Partners reduced its Eli Lilly (LLY) stake by 0.3% in Q3 2026, selling an estimated $11.8K and leaving 3,315 shares worth $3.84M. The position accounts for 0.2% of the portfolio, ranked #50.
Symmetry Partners first reported a position in LLY in Q4 2018 and has held it in 30 quarters since. The position peaked at $11.8M in Q1 2024. 4,106 funds tracked by Wall St. Rank hold LLY as of Q3 2026.
- Symmetry Partners held 3,315 shares of Eli Lilly worth $3.84M as of Q3 2026.
- Symmetry Partners sold 10 Eli Lilly shares in Q3 2026, an estimated $11.8K.
- Eli Lilly made up 0.2% of Symmetry Partners's portfolio in Q3 2026, its #50 holding.
- Symmetry Partners first reported a position in Eli Lilly in Q4 2018 and has held it in 30 quarters since.
- Symmetry Partners's Eli Lilly position peaked at $11.8M in Q1 2024.
- 4,106 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.
Based on Symmetry Partners's 13F filing for Q3 2026, filed 27 Oct 2026.